Skip to main content
. Author manuscript; available in PMC: 2012 Oct 29.
Published in final edited form as: Eur Urol. 2011 Jun 22;61(2):363–369. doi: 10.1016/j.eururo.2011.06.034

Table 3.

Survival time as landmark analyses for those on or off trial at these time points for reasons other than progression or death

CS-205 study
 TAX-327 study
Off study
 On study
 Off study
 On study
Landmark date, d n 1-yr OS (95% CI)* n 1-yr OS (95% CI) n 1-yr OS (95% CI) n 1-yr OS (95% CI)
90 18 58.8 (32.5–77.8) 175 64.4 (56.6–71.2) 17 47.1 (23.0–68.0) 244 73.7 (67.7–78.8)
120 27 35.6 (18.0–53.8) 159 65.0 (56.6–72.1) 20 50.0 (27.1–69.2) 222 72.9 (66.5–78.3)
150 35 44.3 (27.2–60.1) 137 66.0 (57.0–73.6) 20 50.0 (27.1–69.2) 205 73.6 (67.0–79.1)
180 49 42.2 (27.1–56.5) 118 62.0 (51.8–70.7) 26 57.2 (36.1–73.6) 182 74.1 (67.1–79.9)

OS = overall survival; CI = confidence interval.

*

1-yr OS and CI are from the landmark date. To be included, the patient must be alive as of the landmark date and either off study due to reasons other than progression or death or still on study.